申请人:Pharmacia Corporation
公开号:US06750228B1
公开(公告)日:2004-06-15
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor. A contemplated compound corresponds in structure to formula B, below,
揭示了一种治疗过程,包括向患有与病理性基质金属蛋白酶活性相关的病情的宿主投予一种具有出色抑制作用的芳香族砜羟羟肟酸的有效量,该羟羟肟酸对一种或多种基质金属蛋白酶(MMP)酶具有出色的抑制活性,例如MMP-2、MMP-9和MMP-13,同时对至少MMP-1的抑制显著较少。还揭示了具有这些选择性活性的金属蛋白酶抑制剂化合物,制造这种化合物的工艺以及使用抑制剂的药物组合物。一种可考虑的化合物结构对应于下面的公式B,